Rapid Detection and Quantitation of Precipitating Streptokinase-Antibodies

Spöttl, F; Kaiser, R.

doi:10.1055/s-0038-1647730

Cited by 17 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If re-exposed to streptokinase, it may cause anaphylactoid reactions in patients. 12,24 However, our data showed that only 15% of the patients who received intrapleural streptokinase treatment had minor side effects such as chest pain or irritability. These discomforts improved after acetaminophen was used.…”

Section: Discussionmentioning

confidence: 69%

Treatment of Complicated Parapneumonic Pleural Effusion With Intrapleural Streptokinase in Children

Yao

Liu

et al. 2004

Chest

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 69%

Treatment of Complicated Parapneumonic Pleural Effusion With Intrapleural Streptokinase in Children

Yao

Liu

et al. 2004

Chest

View full text Add to dashboard Cite

“…High titers of antibody are present before therapy in some patients or may appear within 2 wk after an initial treatment, complicating long-term therapy (9). Koide et al (10) substantially decreased the reactivity of streptokinase with antibody (antigenicity) by conjugating the protein to polyethylene glycol (PEG; Mr 5,000), a nonantigenic polymer.…”

mentioning

confidence: 99%

A nonantigenic covalent streptokinase-polyethylene glycol complex with plasminogen activator function.

Rajagopalan¹,

Gonias²,

Pizzo³

1985

J. Clin. Invest.

View full text Add to dashboard Cite

Plasmin activity obtained by incubating streptokinase derivatives with plasminogen also was studied as a function of time with each of the PEG-streptokinase derivatives. By this assay, incubations containing PEG-5-streptokinase and unmodified streptokinase demonstrated comparable activity while reaction mixtures containing PEG-2-streptokinase and PEG4-streptokinase were slightly more active. Streptokinpse incubated with plasminogen at a 1:1 molar ratio was extensively degraded after 30 min whereas PEG-2-streptokinase was resistant to plasmin cleavage. The derivatized proteins were radioiodinated and incubated in plastic microtiter plates that were coated with an immunoglobulin fraction containing antibodies to streptokinase. Binding of the PEG-streptokinase adducts was decreased by >95% compared with unmodified streptokinase. Plasminogen activator complexes were formed by reacting the streptokinases with human plasminogen in vitro and the clearance studied in mice. Radioiodinated plasmin in complex with the PEG-streptokinase adducts cleared at a slower rate than did plasmin complexed with unmodified streptokinase. Catabolism of the protease still occurred by a mechanism that involved reaction with a2-macroglobulin as has been described for nonderivatized streptokinase-plasminogen complex (Gonias, S. L., M. Einarsson, and S. V. Pizzo, 1982, J. Clin. Invest., 70:412-423). When more extensive derivatization procedures were utilized, PEG-2-streptokinase preparations were obtained that further prolonged the clearance of complexed 1251-plasmin;however, these adducts did not uniformly retain comparable activity. It is suggested that PEG-streptokinase complexes with greatly reduced antigenicity may be useful in the treatment of thrombotic disorders.Address reprint requests to Dr. Pizzo.

show abstract

“…The duration of therapy, ranging from 1 to 10 days (5)(6)(7)(8)(9)(10)14,15,18,19,29) usually depends on the individual patient's clinical response. Of greatest concern here are the potential complications and side effects of fibrinolytic therapy, which include anaphylactoid reactions and both local and systemic haemorrhage (29)(30)(31). Minor complications, such as chest discomfort, blood-stained pleural fluid and pneumothorax, have also been reported (6,9,13,15).…”

Section: Discussionmentioning

confidence: 99%

Once-daily vs. twice-daily intrapleural urokinase treatment of complicated parapneumonic effusion in paediatric patients: a randomised, prospective study*

Wang

Yao

Yeh

et al. 2006

International Journal of Clinical Practice

View full text Add to dashboard Cite

To evaluate the effective dose frequency (once daily vs. twice daily) of intrapleural urokinase treatment in children who required tube thoracostomy for drainage of a complicated parapneumonic effusion, we designed a randomised prospective study in a tertiary medical centre in Taiwan. From June 2002 to January 2005, 30 paediatric patients with complicated parapneumonic effusion who had received chest tube drainage were randomised 1 : 1 to the once-daily (urokinase 5000-6000 IU/kg/dose) or twice-daily (urokinase 2500-3000 IU/kg/dose) treatment. We compared clinical manifestations and outcomes in both groups. There were no differences in pleural effusion characteristics between the groups. Six patients had Streptococcus pneumoniae, one had Staphylococcus aureus, one had Group A Streptococcus, and 22 had unknown pathogens. There were no significant differences between the once- vs. twice-daily group in the amount of drained pleural fluid (564.9 +/- 422.1 ml vs. 560.5 +/- 198.6 ml, respectively), fever duration after chest tube insertion (4.3 +/- 3.2 days vs. 5.3 +/- 2.7 days), or total admission days (14.3 +/- 3.9 days vs. 14.6 +/- 3.0 days) (p> 0.05 for all). Only two patients (one in each group) required the surgery. Thus, we found that both once- and twice-daily administration of urokinase were similarly efficacious, and resulted in good clinical outcomes. Both obviated the need for surgery in most (93%) cases of pneumonia with complicated parapneumonic effusion in this series. A larger, multicentre study is necessary to verify our findings.

show abstract

Rapid Detection and Quantitation of Precipitating Streptokinase-Antibodies

Cited by 17 publications

References 13 publications

Treatment of Complicated Parapneumonic Pleural Effusion With Intrapleural Streptokinase in Children

Treatment of Complicated Parapneumonic Pleural Effusion With Intrapleural Streptokinase in Children

A nonantigenic covalent streptokinase-polyethylene glycol complex with plasminogen activator function.

Once-daily vs. twice-daily intrapleural urokinase treatment of complicated parapneumonic effusion in paediatric patients: a randomised, prospective study*

Contact Info

Product

Resources

About